AstraZeneca (AZN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in partnership with Daiichi Sankyo, has announced that the FDA has accepted their Biologics License Application for datopotamab deruxtecan, a promising treatment for metastatic HR-positive, HER2-negative breast cancer. The application is supported by Phase III trial results, showing significant improvement in progression-free survival. This breakthrough therapy, also being reviewed for non-small cell lung cancer, could offer a more efficacious and better-tolerated alternative to conventional chemotherapy for patients with advanced disease.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.